Table 1. . Clinical characteristics of 14 relapsed or refractory diffuse large B-cell lymphoma patients.

n	Gender	Age	Diagnosis	Disease status before ASCT	Sites of active disease	Conditioning therapy	MNC cell dose (×108/kg)	CD34 cell dose (×106/kg)	CAR T-cell dose (×106/kg)	CRS max grade	Best response	Duration of best response (month)
1	F	47	DLBCL	SD	Multiple LN	CEAC	4.60	0.44	0.74	1	CR	2.43
2	F	52	DLBCL	SD	Multiple LN	CEAC	4.61	1.15	3	1	CR	8.31+
3	M	32	DLBCL	PD	Pelvic LN	CEAC	7.14	1.14	1.2	2	PD	1.35
4	M	68	DLBCL	SD	Abdomen LN	CEAC	5.94	2.37	2.14	1	CR	20.4+
5	M	44	DLBCL	PD	Abdomen LN	R-CEAC	8.45	12.26	0.88	N	PD	3.65
6	M	28	DLBCL	Relapse	Multiple LN	CEAC	5.06	5.06	7.89	2	CR	16.07+
7	F	56	DLBCL	PD	Breast	CEAC	3.60	4.11	2.37	2	PR	14.82
8	M	22	DLBCL	SD	Cervical LN	R-CEAC	4.72	1.65	1.5	1	PD	5.62
9	F	44	DLBCL	SD	Abdomen LN	R-CEAC	4.70	12	2.49	N	PR	9.88+
10	M	27	DLBCL	PD	Mediastinum	R-CEAC	4.50	7	1.72	2	PR	11.4+
11	F	37	DLBCL	SD	Abdomen LN	R-CEAC	3.51	2.12	5	3	CR	10.91+
12	M	19	DLBCL	PD	Multiple LN	CEAC	7.54	2.76	6.32	2	CR	7.75+
13	M	39	DLBCL	SD	Abdomen LN	CEAC	5.69	6.67	3.59	1	PR	6.6+
14	M	56	DLBCL	PD	Mediastinum	R-CEAC	8.72	5.6	3	2	PR	1.81

ASCT: Autologous hematopoietic stem cell transplantation; CAR: Chimeric antigen receptor; CEAC: Semustine, cytarabine, etoposide and cyclophosphamide; CR: Complete remission; CRS: Cytokine-release syndrome; DLBCL: Diffuse large B-cell lymphoma; F: Female; LN: Lympho nod; M: Male; MNC: Mononuclear cell; N: No CRS; PD: Progressive disease; PR: Partial remission; R: Rituximab; SD: Stable disease.